SCHEMBL2934063

SCHEMBL2934063

CCc1cc2c(cc1O)OC(=O)CC2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH2 P05091 1/20 0.43
ALDH3A1 P30838 1/20 0.43
HSD17B1 P14061 2/20 0.40
MAOB P27338 1/20 0.40
CNR2 P34972 1/20 0.39
KDM4E B2RXH2 3/20 0.39
ALDH1A1 P00352 3/20 0.39
GLA P06280 3/20 0.39
GAA P10253 3/20 0.39
HPGD P15428 3/20 0.39
CASP1 P29466 3/20 0.39
CASP7 P55210 3/20 0.39
HSD17B10 Q99714 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
TSHR P16473 2/20 0.39
MAPT P10636 1/20 0.39
MAPK1 P28482 1/20 0.39
MCL1 Q07820 1/20 0.36
ESR1 P03372 2/20 0.35
ESR2 Q92731 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2934963 0.86 TYR (0.41) ALDH2ALDH3A1MAOBCNR2KDM4E
SCHEMBL2932666 0.84 MEN1 (0.43) ALDH2ALDH3A1KDM4EALDH1A1GLA
SCHEMBL2935573 0.84 MEN1 (0.43) ALDH2ALDH3A1KDM4EALDH1A1GLA
SCHEMBL11791192 0.82 ALDH2 (0.46) ALDH2ALDH3A1MAOBKDM4EALDH1A1
SCHEMBL6832877 0.81 ALDH2 (0.51) ALDH2ALDH3A1MAOBTSHR
SCHEMBL13389081 0.79 ALDH2 (0.53) ALDH2ALDH3A1MAOBKDM4EALDH1A1
SCHEMBL6832714 0.78 ALDH2 (0.51) ALDH2ALDH3A1MAOBTSHR
SCHEMBL2935097 0.76 ALDH2 (0.36) ALDH2ALDH3A1MAOB
SCHEMBL1013631 0.76 ALDH2 (0.42) ALDH2ALDH3A1MAOBKDM4EGLA
SCHEMBL3302778 0.75 ACHE (0.45) ALDH2ALDH3A1ALDH1A1MCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101917989-A Preparation containing chromane-2-one derivatives MERCK PATENT GMBH 2010-12-15 CN disclosed
US-20100291009-A1 PREPARATION COMPRISING CHROMAN-2-ONE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2010-11-18 US disclosed
US-20100291009-A1 PREPARATION COMPRISING CHROMAN-2-ONE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2010-11-18 US disclosed
US-20100291009-A1 PREPARATION COMPRISING CHROMAN-2-ONE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2010-11-18 US disclosed
EP-2229169-A1 PREPARATION CONTAINING CHROMANE-2-ONE DERIVATIVES Merck Patent GmbH (DE) 2010-09-22 EP disclosed
WO-2009089880-A1 PREPARATION CONTAINING CHROMANE-2-ONE DERIVATIVES MERCK PATENT GMBH (DE) 2009-07-23 WO disclosed
WO-2009089880-A1 PREPARATION CONTAINING CHROMANE-2-ONE DERIVATIVES MERCK PATENT GMBH (DE) 2009-07-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100291009-A1 PREPARATION COMPRISING CHROMAN-2-ONE DERIVATIVES RCC1, RB1, RCC2 ALDH2 3443/4885ALDH3A1 2010/4885HSD17B1 1516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.